Pfiz­er's Paxlovid does­n't stack up as well for those who are vac­ci­nat­ed, new da­ta show

Pfiz­er’s Covid-19 an­tivi­ral may end up haul­ing in more than $20 bil­lion this year, and help keep many vul­ner­a­ble peo­ple out of the hos­pi­tal. But new da­ta show the pill doesn’t hold up as well in vac­ci­nat­ed peo­ple as the un­vac­ci­nat­ed.

Up­dat­ed da­ta from the com­pa­ny’s Phase II/III tri­al show the an­tivi­ral whiffed on its pri­ma­ry end­point and of­fered a non-sig­nif­i­cant 51% rel­a­tive risk re­duc­tion for hos­pi­tal­iza­tion or death, with five of 576 on the pill in the tri­al end­ing up in the hos­pi­tal or dy­ing, com­pared to 10 out of 569 on place­bo. Mean­while, a sub-group analy­sis of 721 vac­ci­nat­ed adults with at least one risk fac­tor for pro­gres­sion to se­vere Covid-19 and who were tak­ing the course of Pfiz­er pills al­so failed to reach sta­tis­ti­cal sig­nif­i­cance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER